Description: ISR Immune System Regulation Holding AB (publ) develops immunostimulatory drugs to treat chronic infectious diseases and cancer in Sweden. Its product pipeline includes Covid-19 vaccine, hepatitis B (HBV), human immunodeficiency virus (HIV), and oncology drugs. The company was founded in 2007 and is headquartered in Solna, Sweden.
Home Page: israb.se
Retzius vAeg 11
Solna,
171 65
Sweden
Phone:
46 7 05 42 79 39
Officers
| Name | Title |
|---|---|
| Prof. Ola S. Winqvist M.D., Ph.D. | Co-founder & CEO |
| Mr. Gunnar Jardelöv | Co-Founder & Director |
| Jonas Winqvist | COO & CFO |
| Mr. Johan Sjodahl | Chief Scientific Officer |
| Mr. Nigel Goodman | Chief of Clinical Operations |
| Mr. Jacob Harker | Chief of Manufacturing Officer |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 41.1523 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.6611 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 6 |